Home News

First quarter 2020 results presentation

Operating income, growth figures, profitability and how our products have behaved.

Wed, 13/05/2020 - 00:00 0 min
Download related document
No votes yet
 
Related
Final Decision to award aid of 36.3 million euros for ROVI’s LAISOLID project...
  Madrid, 10 July 2025. Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 9 July 2025, the Technological...
4 min
10/07/2025
ROVI held its 2025 General Shareholders’ Meeting
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
ROVI to receive 36.3 million euros for research into prolonged-release drugs...
  Madrid, 8 May 2025.- Laboratorios Farmacéuticos ROVI, S.A. (“ROVI”) announces that, on 7 May 2025, the Technological Development...
4 min
08/05/2025